ArticleNeurobiology of disease2026
Astrocyte-specific deletion of ceruloplasmin exacerbates oxidative stress and demyelination in the spinal cord in a murine model of multiple sclerosis.
Article in Neurobiology of disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron dysregulation in the central nervous system: implications for autism spectrum disorder.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Astrocytic iron metabolism is essential for maintaining central nervous system (CNS) homeostasis, particularly in the context of neurodegenerative and demyelinating disorders such as multiple sclerosis (MS). Disruption of this regulatory system can result in iron accumulation, heightened neuroinflammation, and demyelination, ultimately accelerating disease progression. Ceruloplasmin (Cp), a copper-containing ferroxidase enzyme highly expressed by astrocytes, plays a pivotal role in facilitating iron efflux and detoxification. However, the precise contribution of astrocytic Cp in demyelinating conditions is currently unknown. To investigate the role of astrocytic iron efflux and Cp in MS pathogenesis, we generated conditional knockout mice lacking Cp specifically in astrocytes (cKO) and induced experimental autoimmune encephalomyelitis (EAE), a widely accepted model of MS. cKO mice exhibited significantly worsened clinical outcomes, including earlier disease onset, increased peak severity, and higher cumulative disease scores during both acute and chronic phases. Histological analyses revealed enhanced microglial activation and lymphocyte infiltration in the spinal cord. These mice also showed elevated demyelination, oxidative stress, lipid peroxidation, and iron accumulation, particularly in spinal cord white matter regions. Similar pathological changes were observed in the cKO brain, with pronounced microglia activation, and immune cell infiltration particularly in the cerebellum. Collectively, these findings highlight a protective role for astrocytic Cp in mitigating neuroinflammation, oxidative damage, and demyelination during EAE. Elucidating the mechanisms by which astrocytic iron regulation influences MS progression may offer novel therapeutic targets focused on glial iron metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.